Virax Biolabs GroupVRAX
13F holders, Q3 2025 (September 30)4holders +2
3new positions
1sold out
$0.60avg. 13F price*
At the end of Q3 2025, 4 institutions reported holding Virax Biolabs Group Ltd. (VRAX) in their 13F filings, up 2 from Q2 2025. 3 opened new positions and 1 sold out. The largest holders were HRT Financial LP ($36K), Virtu Financial LLC ($13K) and National Bank of Canada ($6K).
- Company
- Virax Biolabs Group Ltd.
- CUSIP
- G9495L125
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $51K |
| Exits | 1 | $25K |
All 13F filers, Q2 2025 → Q3 2025: 89,809 shares bought and 30,155 shares sold, net +59,654 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| HRT Financial LP | 0.00% | New | 60,073 | $36K |
| Virtu Financial LLC | 0.00% | New | 21,376 | $13K |
| National Bank of Canada | 0.00% | Add +100.0% | 10,000 | $6K |
| UBS Group AG | 0.00% | New | 3,360 | $2K |
"% of holder's portfolio" is VRAX's weight in each manager's 13F, not the share of Virax Biolabs Group Ltd. the manager owns.